Publications

  1. Hubbard JM, Kim G, Borad MJ, Borad MJ, Johnson E, Qin R, Lensing J, Puttabasavaiah S, Wright J, Erlichman C, Grothey A. Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies. Invest New Drugs 2016 Feb; 34 (1):96-103 Epub 2015 Nov 18
    View PubMed
  2. Hubbard JM. Management of Colorectal Cancer in Older Adults. Clin Geriatr Med 2016 Feb; 32 (1):97-111 Epub 2015 Oct 14
    View PubMed
  3. Thanarajasingam G, Hubbard JM, Sloan JA, Grothey A. The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials. J Natl Cancer Inst 2015 Oct; 107 (10) Epub 2015 Aug 01
    View PubMed
  4. Pachman DR, Ruddy K, Sangaralingham LR, Grothey A, Shah ND, Beutler AS, Hubbard JM, Loprinzi CL. Calcium and Magnesium Use for Oxaliplatin-Induced Neuropathy: A Case Study to Assess How Quickly Evidence Translates Into Practice. J Natl Compr Canc Netw 2015 Sep; 13 (9):1097-101
    View PubMed
  5. Hubbard JM, Jatoi A. Incorporating biomarkers of frailty and senescence in cancer therapeutic trials. J Gerontol A Biol Sci Med Sci. 2015 Jun; 70(6):722-8. Epub 2014 Apr 26.
    View PubMed
  6. Hubbard JM, Grothey A. Colorectal cancer in 2014: progress in defining first-line and maintenance therapies. Nat Rev Clin Oncol. 2015 Feb; 12(2):73-4. Epub 2015 Jan 06.
    View PubMed
  7. Kasi PM, Thanarajasingam G, Finnes HD, Villasboas Bisneto JC, Hubbard JM, Grothey A. Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer. Case Rep Oncol Med. 2015; 2015:420159. Epub 2015 May 21.
    View PubMed
  8. Leal AD, Hubbard J, Sargent D, Grothey A. New adjuvant trial designs in colon cancer Current Colorectal Cancer Reports 2015; 11 (6):326-34
  9. Hubbard JM, Cohen HJ, Muss HB. Incorporating biomarkers into cancer and aging research. J Clin Oncol 2014 Aug 20; 32 (24):2611-6 Epub 2014 July 28
    View PubMed
  10. Hubbard JM, Grothey AF, McWilliams RR, Buckner JC, Sloan JA. Physician perspective on incorporation of oncology patient quality-of-life, fatigue, and pain assessment into clinical practice. J Oncol Pract. 2014 Jul; 10(4):248-53. Epub 2014 Mar 25.
    View PubMed
  11. Alliance for Clinical Trials in Oncology, Gonsalves WI, Mahoney MR, Sargent DJ, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA, Goldberg RM, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Chan E, Nair S, Berenberg JL, McWilliams RR. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst 2014 Jul; 106 (7) Epub 2014 June 12
    View PubMed
  12. Sridharan M, Hubbard J, Grothey A. Colorectal Cancer: How Emerging Molecular Understanding Affects Treatment Decisions Oncology. 2014 Feb 15. [Epub ahead of print]
  13. Lapid MI, Atherton PJ, Clark MM, Kung S, Richardson JW, Cheville AL, Dyrbye LN, Hubbard JM, Piderman KM, Shanafelt TD, Sloan JA, West CP, Schott DK, Rummans TA. Geriatric and non-geriatric cancer caregivers: Perceived benefits of technology. Gerontechnology. 2014; 13(2):231.
  14. Hubbard JM, Grothey A. Adolescent and young adult colorectal cancer. J Natl Compr Canc Netw. 2013 Oct 1; 11(10):1219-25.
    View PubMed
  15. Hubbard JM, Alberts SR. Alternate dosing of cetuximab for patients with metastatic colorectal cancer. Gastrointest Cancer Res. 2013 Mar; 6(2):47-55.
    View PubMed
  16. Hubbard J, Thomas DM, Yothers G, Green E, Blanke C, O'Connell MJ, Labianca R, Shi Q, Bleyer A, de Gramont, Sargent D. Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set. J Clin Oncol. 2012 Jul 1; 30(19):2334-9. Epub 2012 May 21
    View PubMed
  17. Lewis M, Hubbard J. Treatment of liver-limited disease from colorectal cancer. Journal of Interventional Oncology. March 2012; 2(1):15-24.
  18. Hubbard J, Erlichman C, Toft DO, Qin R, Stensgard BA, Felten S, Ten Eyck C, Batzel G, Ivy SP, Haluska P. Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors. Invest New Drugs. 2011 Jun; 29(3):473-80. Epub 2010 Jan 15
    View PubMed
  19. Hubbard JM, Grothey A, Sargent DJ. Systemic therapy for elderly patients with gastrointestinal cancer. Clin Med Insights Oncol. 2011; 5:89-99. Epub 2011 Apr 25.
    View PubMed
  20. Lewis MA, Hubbard J. Multimodal liver-directed management of neuroendocrine hepatic metastases. Int J Hepatol. 2011; 2011:452343. Epub 2011 Oct 29.
    View PubMed
  21. Hubbard J, Grothey A. Reduced chemotherapy duration: A good idea? Current Colorectal Cancer Reports. 2011; 7(3):241-5.
  22. Hubbard J, Grothey A. Antiangiogenesis agents in colorectal cancer. Curr Opin Oncol. 2010 Jul; 22(4):374-80.
    View PubMed
  23. Hubbard JM, Alberts SR. Treatment of liver-limited metastatic colorectal cancer. Cancer J. 2010 May-Jun; 16(3):235-40.
    View PubMed
  24. de Gramont, Hubbard J, Shi Q, O'Connell MJ, Buyse M, Benedetti J, Bot B, O'Callaghan C, Yothers G, Goldberg RM, Blanke CD, Benson A, Deng Q, Alberts SR, Andre T, Wolmark N, Grothey A, Sargent D. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. J Clin Oncol. 2010 Jan 20; 28(3):460-5. Epub 2009 Dec 14.
    View PubMed
  25. Hubbard J, Grothey A. Strategies for managing chemotherapy-induced sensory neuropathy. Current Colorectal Cancer Reports. 2010; 6(3):126-32.
  26. Hubbard J, Sargent D. Evidence for Cure by Adjuvant Chemotherapy in Colorectal Cancer Review. American Journal of Hematology/Oncology. 2009; 8(9):419-24.
  27. Turja J, Grothey A. Individualizing therapy for metastatic colorectal cancer. Oncology (Williston Park). 2008 Nov 30; 22(13):1479-81.
    View PubMed